Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

<ul><li>On September 13, 2024, ESSA Pharma Inc. (EPIX) announced that updated dose escalation data for the ongoing Phase 1/2 clinical trial of masofaniten (EPI-7386) in combination with enzalutamide (Enz) was presented at the 2024 European Society for Medicinal Oncology (ESMO) Congress.</li><li>With 15.2 months of follow up, neither the median radiographic progression free survival (rPFS) or time to PSA progression (TTPP) have been reached.</li><li>Additionally, since the last trial update at ASCO-GU, one more patient has achieved PSA90, bringing the total to 14/16 (88%).</li></ul>

On September 13, 2024, ESSA Pharma Inc. (EPIX) announced that updated dose escalation data for the ongoing Phase 1/2 clinical trial of masofaniten (EPI-7386) in combination with enzalutamide (Enz) was presented at the 2024 European Society for Medicinal Oncology (ESMO) Congress.With 15.2 months of follow up, neither the median radiographic progression free survival (rPFS) or time to PSA progression (TTPP) have been reached.Additionally, since the last trial update at ASCO-GU, one more patient has achieved PSA90, bringing the total to 14/16 (88%).

EPIX: Masofaniten Combination Therapy with Enzalutamide Increases rPFS  Increasing Valuation to 33 per Share

<ul><li>On August 5, 2024, ESSA Pharma Inc. (EPIX) announced financial results for the third quarter of fiscal year 2024 that ended June 30, 2024 and provided a business update.</li><li> ESSA is currently studying its lead compound, masofaniten (EPI-7386), in two clinical trials: EPI-7386-CS-001 and EPI-7386-CS-010.</li><li>Full results from the monotherapy arm of the -001 trial will be presented at a scientific conference in the second half of 2024 while enrollment continues in the two combination arms.</li></ul>

On August 5, 2024, ESSA Pharma Inc. (EPIX) announced financial results for the third quarter of fiscal year 2024 that ended June 30, 2024 and provided a business update. ESSA is currently studying its lead compound, masofaniten (EPI-7386), in two clinical trials: EPI-7386-CS-001 and EPI-7386-CS-010.Full results from the monotherapy arm of the -001 trial will be presented at a scientific conference in the second half of 2024 while enrollment continues in the two combination arms.

EPIX: Updated Masofaniten plus Enzalutamide Dose Escalation Data to be Presented at ESMO 2024 

<ul><li>On May 14, 2024, ESSA Pharma Inc. (EPIX) announced financial results for the second quarter of fiscal year 2024 that ended March 31, 2024 and provided a business update.</li><li> ESSA is currently studying its lead compound, masofaniten (EPI-7386), in two clinical trials: EPI-7386-CS-001 and EPI-7386-CS-010.</li><li>The -001 trial consists of Part A monotherapy treatment and Part B combination therapy of masofaniten plus abiraterone acetate/prednisone (Cohort 1 mHSPC or mCRPC) or with apalutamide following 12 weeks of monotherapy therapy (Cohort 2 nmCRPC).</li></ul>

On May 14, 2024, ESSA Pharma Inc. (EPIX) announced financial results for the second quarter of fiscal year 2024 that ended March 31, 2024 and provided a business update. ESSA is currently studying its lead compound, masofaniten (EPI-7386), in two clinical trials: EPI-7386-CS-001 and EPI-7386-CS-010.The -001 trial consists of Part A monotherapy treatment and Part B combination therapy of masofaniten plus abiraterone acetate/prednisone (Cohort 1 mHSPC or mCRPC) or with apalutamide following 12 weeks of monotherapy therapy (Cohort 2 nmCRPC).

EPIX: Updated Data from Phase 1 Trial of Masofaniten and Enzalutamide Expected in 2H24 

Research from Water Tower Research, Water Tower Research

Water Tower Research

Research from Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Equity Research Firm

Thematic (Sector/Industry)

<ul><li>We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&amp;A.</li><li>Last week, NVO had all semaglutide dosages listed available on the FDA drug shortage list, pressuring compounded GLP-1 seller HIMS.</li><li>ABBV acquired a private Alzheimer’s biotech, boosting neuro developers PRTA, VIGL, and ALEC.</li></ul>

We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&amp;A.Last week, NVO had all semaglutide dosages listed available on the FDA drug shortage list, pressuring compounded GLP-1 seller HIMS.ABBV acquired a private Alzheimer’s biotech, boosting neuro developers PRTA, VIGL, and ALEC.

Biopharma Week in Review - November 4, 2024

Canada

ESSA Pharma Inc., is a pharmaceutical company focused on the development of small molecule drugs for the treatment of prostate cancer.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Essa Pharma (EPIX US)

EPIX: Updated Masofaniten plus Enzalutamide Dose Escalation Data to be Presented at ESMO 2024

On August 5, 2024, ESSA Pharma Inc. (EPIX) announced financial results for the third quarter of fiscal year 2024 that ended June 30, 2024 and...

Zacks Small Cap Research

EPIX: Updated Data from Phase 1 Trial of Masofaniten and Enzalutamide Expected in 2H24

On May 14, 2024, ESSA Pharma Inc. (EPIX) announced financial results for the second quarter of fiscal year 2024 that ended March 31, 2024 and...

Zacks Small Cap Research

Biopharma Week in Review - November 4, 2024

Last week, NVO had all semaglutide dosages listed available on the FDA drug shortage list, pressuring compounded GLP-1 seller HIMS.

Water Tower Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

EPIX: Masofaniten Combination Therapy with Enzalutamide Increases rPFS Increasing Valuation to 33 per Share

On September 13, 2024, ESSA Pharma Inc. (EPIX) announced that updated dose escalation data for the ongoing Phase 1/2 clinical trial of masofaniten...

Zacks Small Cap Research

EPIX: Updated Masofaniten plus Enzalutamide Dose Escalation Data to be Presented at ESMO 2024

On August 5, 2024, ESSA Pharma Inc. (EPIX) announced financial results for the third quarter of fiscal year 2024 that ended June 30, 2024 and...

Zacks Small Cap Research

EPIX: Updated Data from Phase 1 Trial of Masofaniten and Enzalutamide Expected in 2H24

On May 14, 2024, ESSA Pharma Inc. (EPIX) announced financial results for the second quarter of fiscal year 2024 that ended March 31, 2024 and...

Zacks Small Cap Research

Biopharma Week in Review - November 4, 2024

Last week, NVO had all semaglutide dosages listed available on the FDA drug shortage list, pressuring compounded GLP-1 seller HIMS.

Water Tower Research